Table 5 Comparison of antithrombotic therapy between the pre-campaign and campaign periods
|  | Pre-campaign period N = 86 | Campaign period N = 90 |
|---|---|---|
Antithrombotic therapy | 60 (69.8) | 70 (77.8) |
 Oral anticoagulant agents | 52 (60.5) | 62 (68.9) |
  Warfarin | 11 (21.2) | 11 (17.7) |
  DOACs | 41 (78.8) | 51 (82.3) |
 Antiplatelet agents | 12 (14.0) | 10 (11.1) |
CHADS2 score low (score, 0) | N = 4 | N = 6 |
 Oral anticoagulant agents | 4 (100.0) | 2 (33.3) |
  Warfarin | 0 (0.0) | 0 (0.0) |
  DOACs | 4 (100.0) | 2 (100.0) |
CHADS2 score Intermediate (score, 1) | N = 13 | N = 10 |
 Oral anticoagulant agents | 7 (53.8) | 9 (90.0) |
  Warfarin | 1 (14.3) | 3 (33.3) |
  DOACs | 6 (85.7) | 6 (66.7) |
CHADS2 score high (score, ≥2) | N = 69 | N = 74 |
 Oral anticoagulant agents | 41 (59.4) | 51 (68.9) |
  Warfarin | 10 (24.4) | 8 (15.7) |
  DOACs | 31 (75.6) | 43 (84.3) |
OAC therapy based on JCS 2013 guidelines | 48 (55.8) | 64 (71.1) |